Literature DB >> 2550662

Trojan horse lymphocytes: a vesicular stomatitis virus-specific T-cell clone lyses target cells by carrying virus.

R C Hom1, G Soman, R Finberg.   

Abstract

We have isolated a vesicular stomatitis virus (VSV)-specific CD4+ CD8- murine T-cell clone. This clone proliferates only in response to VSV and lyses infected tumor cells bearing class II major histocompatibility antigens in short-term chromium release assays. In addition, the cell has VSV antigens on its surface and is capable of killing uninfected tumor cells without major histocompatibility antigen restriction in a 2-day assay. This latter cytolytic activity is eliminated by anti-VSV antibody, indicating that its lytic activity is provided by the virus. [35S]methionine labeling and immunoprecipitation experiments demonstrated that viral protein translation is initiated after incubation of the clone with a tumor target cell, defining this as the mechanism of its cytolytic activity.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550662      PMCID: PMC251029          DOI: 10.1128/JVI.63.10.4157-4164.1989

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  30 in total

1.  Generation of cytolytic T lymphocytes in vitro. IX. induction of secondary CTL responses in primary long-term MLC by supernatants from secondary MLC.

Authors:  J E Ryser; J C Cerottini; K T Brunner
Journal:  J Immunol       Date:  1978-02       Impact factor: 5.422

2.  Interaction between CD4 and class II MHC molecules mediates cell adhesion.

Authors:  C Doyle; J L Strominger
Journal:  Nature       Date:  1987 Nov 19-25       Impact factor: 49.962

3.  Long-term persistent vesicular stomatitis virus and rabies virus infection of cells in vitro.

Authors:  J J Holland; L P Villarreal; R M Welsh; M B Oldstone; D Kohne; R Lazzarini; E Scolnick
Journal:  J Gen Virol       Date:  1976-11       Impact factor: 3.891

4.  Cytotoxic T lymphocyte sequential killing of immobilized allogeneic tumor target cells measured by time-lapse microcinematography.

Authors:  T L Rothstein; M Mage; G Jones; L L McHugh
Journal:  J Immunol       Date:  1978-11       Impact factor: 5.422

5.  Enumeration of activated thymus-derived lymphocytes by the virus plaque assay.

Authors:  S Kano; B R Bloom; M L Howe
Journal:  Proc Natl Acad Sci U S A       Date:  1973-08       Impact factor: 11.205

6.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

7.  Virus-lymphocyte interactions. III. Biologic parameters of a virus variant that fails to generate CTL and establishes persistent infection in immunocompetent hosts.

Authors:  M B Oldstone; M Salvato; A Tishon; H Lewicki
Journal:  Virology       Date:  1988-06       Impact factor: 3.616

8.  L3T4+ cytotoxic T lymphocytes specific for class I H-2 antigens are activated in primary mixed lymphocyte reactions.

Authors:  S Macphail; O Stutman
Journal:  J Immunol       Date:  1987-12-15       Impact factor: 5.422

9.  Abrogation of diabetes in BB rats by acute virus infection. Association of viral-lymphocyte interactions.

Authors:  P L Schwimmbeck; T Dyrberg; M B Oldstone
Journal:  J Immunol       Date:  1988-05-15       Impact factor: 5.422

10.  Selective viral immunosuppression of the graft-versus-host reaction.

Authors:  T J Romano; M Nowakowski; B R Bloom; G J Thorbecke
Journal:  J Exp Med       Date:  1977-03-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Systemic lupus erythematosus: RNA-protein autoantigens, models of disease heterogeneity, and theories of etiology.

Authors:  J B Harley; R H Scofield
Journal:  J Clin Immunol       Date:  1991-11       Impact factor: 8.317

2.  Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection.

Authors:  L H Nguyen; D M Knipe; R W Finberg
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.